These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26042612)

  • 1. Preclinical development of HIvax: Human survivin highly immunogenic vaccines.
    Hoffmann PR; Panigada M; Soprana E; Terry F; Bandar IS; Napolitano A; Rose AH; Hoffmann FW; Ndhlovu LC; Belcaid M; Moise L; De Groot AS; Carbone M; Gaudino G; Matsui T; Siccardi A; Bertino P
    Hum Vaccin Immunother; 2015; 11(7):1585-95. PubMed ID: 26042612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fowlpox-based survivin vaccination for malignant mesothelioma therapy.
    Bertino P; Panigada M; Soprana E; Bianchi V; Bertilaccio S; Sanvito F; Rose AH; Yang H; Gaudino G; Hoffmann PR; Siccardi A; Carbone M
    Int J Cancer; 2013 Aug; 133(3):612-23. PubMed ID: 23335100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The study of anti-tumor activities of DC vaccine loaded with multi-epotipes of survivin].
    Guo M; Wang XY; Song WZ; Li XN; Liang X; Li Y; Huang ZL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Nov; 27(11):1180-3. PubMed ID: 22078442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antitumor effect of human cord blood-derived dendritic cells modified by the livin α gene in lung cancer cell lines.
    Chen H; Jin Y; Chen T; Zhang M; Ma W; Xiong X; Tao X
    Oncol Rep; 2013 Feb; 29(2):619-27. PubMed ID: 23152000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes.
    Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K
    Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
    Widenmeyer M; Griesemann H; Stevanović S; Feyerabend S; Klein R; Attig S; Hennenlotter J; Wernet D; Kuprash DV; Sazykin AY; Pascolo S; Stenzl A; Gouttefangeas C; Rammensee HG
    Int J Cancer; 2012 Jul; 131(1):140-9. PubMed ID: 21858810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway.
    Wei Y; Sun Y; Song C; Li H; Li Y; Zhang K; Gong J; Liu F; Liu Z; August JT; Jin B; Yang K
    J Gene Med; 2012 May; 14(5):353-62. PubMed ID: 22438278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.
    Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos AK; Quest AF; Kiessling R
    Cancer Immunol Immunother; 2010 Jan; 59(1):81-92. PubMed ID: 19526360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.